Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B Wake; C Hyde; S Bryan; PM Barton; F Song; A Fry-Smith; C Davenport

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

B Wake, C Hyde, S Bryan, PM Barton, F Song, A Fry-Smith, C Davenport

Research output: Contribution to journal › Article

22 Citations (Scopus)

Original language	English
Pages (from-to)	1-85
Number of pages	85
Journal	Health Technology Assessment
Volume	6
Issue number	3
Publication status	Published - 2002

Cite this

@article{bb32eaaa90484b25b80c97e77bcf4fd7,

title = "Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation",

author = "B Wake and C Hyde and S Bryan and PM Barton and F Song and A Fry-Smith and C Davenport",

year = "2002",

language = "English",

volume = "6",

pages = "1--85",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "National Co-ordinating Centre for HTA",

number = "3",

}

TY - JOUR

T1 - Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

AU - Wake, B

AU - Hyde, C

AU - Bryan, S

AU - Barton, PM

AU - Song, F

AU - Fry-Smith, A

AU - Davenport, C

PY - 2002

Y1 - 2002

M3 - Article

VL - 6

SP - 1

EP - 85

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 3

ER -